Compare MCR & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCR | ACIU |
|---|---|---|
| Founded | 1989 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 262.2M | 213.3M |
| IPO Year | N/A | 2015 |
| Metric | MCR | ACIU |
|---|---|---|
| Price | $6.26 | $2.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 79.2K | ★ 291.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 8.52% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $495.67 |
| P/E Ratio | $16.47 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.57 | $1.43 |
| 52 Week High | $6.57 | $4.00 |
| Indicator | MCR | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 53.93 | 30.50 |
| Support Level | $6.25 | $2.45 |
| Resistance Level | $6.34 | $3.19 |
| Average True Range (ATR) | 0.04 | 0.18 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 62.97 | 7.29 |
MFS Charter Income Trust is a United States-based closed-end fund. Its investment objective is to seek high current income, but may also consider capital appreciation. The fund invests the assets in Debt Instruments, Corporate Bonds, U.S. Government Securities, Foreign Government Securities, Securitized Instruments, Derivatives, Principal Risks, Debt Management Risk, Investment Selection Risk, Interest Rate Risk, Credit Risk, Foreign Risks, Emerging Markets Risk, Currency Risk, Leveraging Risk, Operational and Cybersecurity Risk, Active and Frequent Trading, and etc of different market countries.
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.